The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 trial of darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with AR targeting agents and non-progressive on a subsequent taxane (SAKK 08/16).
 
Richard Cathomas
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche; Sanofi
 
Stefanie Hayoz
No Relationships to Disclose
 
Andrea Corinne Fuhrer
No Relationships to Disclose
 
Christine Biaggi Rudolf
No Relationships to Disclose
 
Augusto Pedrazzini
No Relationships to Disclose
 
Giuseppe Procopio
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Ipsen; Janssen
 
Silke Gillessen
Consulting or Advisory Role - Active Biotech (Inst); Active Biotech (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Curevac (Inst); CureVac (Inst); Ferring (Inst); Ferring (Inst); Innocrin Pharma (Inst); Janssen (Inst); MaxiVax ; Novartis (Inst); Orion (Inst); Roche (Inst); Sanofi; Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - Diverse Companies
Other Relationship - Astellas Medivation; ESSA; Nektar; ProteoMediX